Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.47 | N/A | +3.30% |
management commentary, guidance changes, and full analysis available with Pro.
| +3.30% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS performance, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS results this quarter.
Our focus remains on delivering value to our shareholders.
Gilead Sciences reported a slight beat on EPS, indicating better-than-expected profitability. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, which could suggest a wait-and-see approach from the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IMPERIAL OIL LTD
Feb 1, 2013